PAM
BBIO icon

Panagora Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Panagora Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
25,898
-716,219
-97% -$50.2M 0.01% 635
2026
Q1 		$55.1M Buy
742,117
+3,274
+0.4% +$237K 0.21% 108
2025
Q4 		$56.5M Buy
738,843
+9,319
+1% +$612K 0.2% 111
2025
Q3 		$37.9M Buy
729,524
+16,033
+2% +$782K 0.15% 138
2025
Q2 		$30.8M Buy
713,491
+97,239
+16% +$3.54M 0.14% 143
2025
Q1 		$21.3M Buy
616,252
+107,445
+21% +$3.62M 0.11% 170
2024
Q4 		$14M Sell
508,807
-240,012
-32% -$6.2M 0.06% 203
2024
Q3 		$19.1M Buy
748,819
+20,856
+3% +$548K 0.09% 175
2024
Q2 		$18.4M Buy
727,963
+312,686
+75% +$8.55M 0.09% 165
2024
Q1 		$12.8M Buy
415,277
+222,435
+115% +$7.56M 0.07% 210
2023
Q4 		$7.79M Buy
192,842
+16,298
+9% +$489K 0.04% 259
2023
Q3 		$4.66M Buy
176,544
+36,299
+26% +$1.03M 0.03% 313
2023
Q2 		$2.41M Buy
+140,245
New +$2.11M 0.01% 492
2021
Q3 		– Sell
-4,060
Closed -$247K – 1766
2021
Q2 		$247K Buy
+4,060
New +$232K ﹤0.01% 1600

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Panagora Asset Management's BBIO Position: Q2 2026 in Review

Panagora Asset Management reduced its BridgeBio Pharma (BBIO) stake by 97% in Q2 2026, selling an estimated $50.2M and leaving 25,898 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #635.

Panagora Asset Management first reported a position in BBIO in Q2 2021 and has held it in 14 quarters since. The position peaked at $56.5M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Panagora Asset Management held 25,898 shares of BridgeBio Pharma worth $1.93M as of Q2 2026.
  • Panagora Asset Management sold 716,219 BridgeBio Pharma shares in Q2 2026, an estimated $50.2M.
  • BridgeBio Pharma made up 0.01% of Panagora Asset Management's portfolio in Q2 2026, its #635 holding.
  • Panagora Asset Management first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 14 quarters since.
  • Panagora Asset Management's BridgeBio Pharma position peaked at $56.5M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.